Alpha Tau Medical Shares Gain on Positive Interim Results for Glioblastoma Therapy
By Kelly CloonanShares of Alpha Tau Medical gained on positive interim trial results for its alpha-radiation cancer therapy Alpha DaRT in patients with recurrent glioblastoma.The stock climbed 13% to $15.15 in premarket trading on Monday. At Friday's market close, the share price had more than doub…